Andere Kunden interessierten sich auch für
![Pain Management for People with Serious Illness in the Context of the Opioid Use Disorder Epidemic]( "Pain Management for People with Serious Illness in the Context of the Opioid Use Disorder Epidemic")
Pain Management for People with Serious Illness in the Context of the Opioid Use Disorder Epidemic61,99 €![Medications for Opioid Use Disorder Save Lives]( "Medications for Opioid Use Disorder Save Lives")
Medications for Opioid Use Disorder Save Lives60,99 €![Opportunities to Improve Opioid Use Disorder and Infectious Disease Services]( "Opportunities to Improve Opioid Use Disorder and Infectious Disease Services")
Opportunities to Improve Opioid Use Disorder and Infectious Disease Services71,99 €![Advancing Therapeutic Development for Pain and Opioid Use Disorders Through Public-Private Partnerships]( "Advancing Therapeutic Development for Pain and Opioid Use Disorders Through Public-Private Partnerships")
Advancing Therapeutic Development for Pain and Opioid Use Disorders Through Public-Private Partnerships49,99 €![Framing Opioid Prescribing Guidelines for Acute Pain]( "Framing Opioid Prescribing Guidelines for Acute Pain")
Framing Opioid Prescribing Guidelines for Acute Pain76,99 €![Pain Management and the Opioid Epidemic]( "Pain Management and the Opioid Epidemic")
Pain Management and the Opioid Epidemic84,99 €![The Politics of the Opioid Epidemic]( "The Politics of the Opioid Epidemic")
The Politics of the Opioid Epidemic18,99 €
Methadone is a Food and Drug Administration- (FDA-) approved medication for treating opioid use disorder (OUD), a chronic brain disease that affects more than 2.7 million people in the United States aged 12 and older. Despite its effectiveness in saving lives, many barriers impede access to, initiation of, and retention in methadone treatment for OUD. To address these barriers, on March 3 and 4, 2022, the National Academies of Sciences, Engineering, and Medicine hosted a workshop on "Methadone Treatment for Opioid Use Disorder: Examining Federal Regulations and Laws," at the request of the Office of National Drug Control Policy in the Executive Office of the President. This publication summarizes the presentation and discussion of the workshop.